IL- 6 Gene (174G/C) Single Nucleotide Polymorphism as an Indicator of COVID-19 Severity in Egyptian Patients
- Conditions
- Covid19
- Interventions
- Diagnostic Test: interleuken 6 level measurmentDiagnostic Test: Interleukin-6 Gene-174C detection
- Registration Number
- NCT04544033
- Lead Sponsor
- Tanta University
- Brief Summary
Although the direct damage from the viruses contributes to the initiation of the disease, the cytokine storm caused by COVID-19 plays a vital role in the development of acute lung injury and adult respiratory distress syndrome. IL-6, a kind of pleiotropic cytokine, is expressed by immune cells such as DC, monocytes, macrophages, B cells, and subsets of activated T cells, as well as by non-immune cells like fibroblasts, epithelial cells, and keratinocytes
- Detailed Description
The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a public health emergency of international concern the epidemic has put public health systems under severe strain both in western countries and in the developing world. SARS-CoV-2 displays a more efficient transmission pattern when compared with SARS-CoV and MERS-CoV. Although the direct damage from the viruses contributes to the initiation of the disease, the cytokine storm caused by COVID-19 plays a vital role in the development of acute lung injury and adult respiratory distress syndrome.
IL-6, a kind of pleiotropic cytokine, is expressed by immune cells such as DC, monocytes, macrophages, B cells, and subsets of activated T cells, as well as by non-immune cells like fibroblasts, epithelial cells, and keratinocytes. It contributes to the pathogenesis of inflammatory or autoimmunity diseases. Excessive production of IL-6 leads to serious disease progression in viral infection. The IL-6 gene is located on chromosome 7 and several polymorphisms have been reported. The most frequently studied polymorphism is the single nucleotide polymorphism (SNP) 174C and - 174G in the promoter region, which has been associated with transcription rates of IL6. The incidence of IL-6-174C alleles is approximately 40%among the general Population. The G allele 174 SNP is coupled with the increased transcription upon endotoxin and IL-1β stimulation, IL-6 -174C allele carrier status is associated with higher level of IL-6 production and more severe forms of 4 pneumonia in general. This analysis strengthens the notion that IL-6 plays a pivotal role in novel coronavirus pneumonia (NCP) progression, it was IL-6-174 C allele rather than G allele that contributed to the risk of sepsis induced by Pneumonia
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 120
- Patients proved to be COVID-19 positive
- clinical correlation with positive PCR.
- clinical correlation with positive rapid antigen detection test.
- Patients with chronic infections including hepatitis B or C infection.
- Immunodeficiency virus (HIV) infections.
- Autoimmune diseases including systemic lupus erthromatosus and rheumatoid arthritis.
- Any malignancy or chronic inflammation
- Any other chest diseases (TB)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description moderate group interleuken 6 level measurment Amendment to MOH COVID-19 Protocol: * Patient with non-specific and specific respiratory infection (pneumonia). * CT changes in both lungs (Ground glass opacities (GGO), Crazy paving, consolidation, multiple interlobular thickening). mild group interleuken 6 level measurment Amendment to MOH COVID-19 Protocol: * Patient with mild clinical symptoms \& clinically table. * CT changes: Appearance in the lung from no changes to just subpleural nodule or subpleural line. mild group Interleukin-6 Gene-174C detection Amendment to MOH COVID-19 Protocol: * Patient with mild clinical symptoms \& clinically table. * CT changes: Appearance in the lung from no changes to just subpleural nodule or subpleural line. severe group Interleukin-6 Gene-174C detection Amendment to MOH COVID-19 Protocol: * Patients with respiratory distress (RR \> 30/min, Sa02 \< 92 at room air). * Chest radiology showing more than 50% lesion or progressive lesion within 24 to 48 hours. * CT changes in both lungs: extensive (GGO, Crazy paving, consolidation, multiple interlobular thickening, fan shaped distribution of peribronchial thickening). moderate group Interleukin-6 Gene-174C detection Amendment to MOH COVID-19 Protocol: * Patient with non-specific and specific respiratory infection (pneumonia). * CT changes in both lungs (Ground glass opacities (GGO), Crazy paving, consolidation, multiple interlobular thickening). severe group interleuken 6 level measurment Amendment to MOH COVID-19 Protocol: * Patients with respiratory distress (RR \> 30/min, Sa02 \< 92 at room air). * Chest radiology showing more than 50% lesion or progressive lesion within 24 to 48 hours. * CT changes in both lungs: extensive (GGO, Crazy paving, consolidation, multiple interlobular thickening, fan shaped distribution of peribronchial thickening).
- Primary Outcome Measures
Name Time Method interleuken- 6 gene (174G/C) single nucleotide polymorphism "through study completion, an average of 4 months the correlation between IL- 6 gene (174G/C) single nucleotide polymorphism with the pathogenesis of COVID-19 severity in Egyptian patients.
- Secondary Outcome Measures
Name Time Method interleukin 6 level "through study completion, an average of 4 months the correlation between IL-6 with the pathogenesis of COVID-19 severity in Egyptian patients.
Trial Locations
- Locations (1)
Bsant Safwat Kasem
🇪🇬Tanta, El Gharbyia, Egypt